Audit: QRS - Amanita muscaria for Health & Longevity

Audit conducted on 29/09/2026 15:08 using AI4L / Opus 5.5

Iterations

Summary

Items	Count
Total	94
Passed	87
Failed	0
N/A	7
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	All gate items, tier items, protocol/time cells, markers, cadence and qualitative items trace to ER text (Key Interactions & Contraindications, Expected Benefits, Potential Risks & Side Effects, Therapeutic Protocol, Practical Considerations, Monitoring Protocol & Defining Success).
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	Cautious phrasing carried over: “no safe interval established”, “User reports only; no study has measured time to any lasting benefit”, “No controlled study of the mushroom itself has measured these effects”.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	“absolute contraindication” and “avoid” classes preserved; Low/Speculative tiers kept as in ER; no claim strengthened or softened.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Contraindications and interactions come from the ER interactions/populations list; benefits and risks keep their ER tiers; no modifying factor surfaced as caution or side effect.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, study citations, expert names, NCT IDs or brand names appear; “1967 self-experiment” matches ER Protocol.
1.6	The QRS does not introduce new attributions.	🟢

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Measured, evidence-first tone mirrors the ER Conclusion.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢
2.4	The QRS avoids language that implies medical or clinical advice	🟢	Severity words (avoid, caution, monitor) mirror ER classes; no personal medical advice.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person address found.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Plain wording; technical thresholds (GOLD stage, eGFR) kept only as ER qualifiers and biomarker names.
2.8	Information is presented in a concise and very compact manner	🟢
2.9	It DOES NOT address the reader directly	🟢
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	Lede weighs harms against benefits for adults seeking sleep, stress and pain benefits, as in the ER Conclusion.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	No “anti-aging” wording.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt.	🟢	No colloquial route or adverse-event terms (pill, by mouth, shot) found.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: * Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment” * Gate headings: “Contraindications”, “Key Interactions” * Tier labels: “High”, “Medium”, “Low”, “Speculative” * Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All fixed headings, gate headings, tier labels and column headers match the template.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All template span names present; marker_# and qualitative_item_# expanded to numbered instances.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	Diff against template shows only checklist-addressed spans changed; website spans untouched.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	🟢	Empty ER tiers (High/Medium) handled by hiding spans; the only empty-state phrase used (“No established target”) follows the ER Monitoring table’s own phrasing.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	Protocol labels “No validated protocol”, “Muscimol-dosed approach”, “Single versus split dosing” are ER bold labels verbatim; marker names match ER table.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji found in QRS source.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Sections condensed (example drug lists trimmed, explanations stripped); rendered layout not checked per “No Rendered Check”.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	No leading/trailing whitespace; duration quoted because it contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	26.9.29 matches QRS.md version.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	2026-0929-1434
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	Opus
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	Opus 5.5
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	“Amanita muscaria for Health & Longevity - Quick Reference Sheet”
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	09/29/2026
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Opus 5.5
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] opens by saying what the intervention is — its kind (e.g., dietary supplement, prescription medication, peptide, plant, procedure, practice) — and what it is used for, in plain language, before any verdict on the evidence	🟢	Opens with “a mind-altering mushroom that adults use hoping for better sleep, less stress and pain relief”.
7.2	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Condenses the three Conclusion paragraphs, including its closing verdict.
7.3	[at_a_glance] is no longer than 70 words	🟢	70 words (script count).
7.4	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢
7.5	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms or specialist terms.
7.6	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢
7.7	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢
8.2	[stop_items] represent the Contraindications from the ER	🟢	All 9 ER populations plus opioids (ER: absolute contraindication) listed.
8.3	Individual [stop_items] are formatted as <li></li>	🟢
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Qualifiers kept: under 18, past 12 months, 30 days of stopping, GOLD stage 3–4, 15+ breathing pauses per hour, below 50 beats per minute, eGFR below 30, 75 and older, 24 hours either side.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	ER uses no ranking notation.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	Section is populated, as the ER names populations to avoid.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	Section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	All ER interaction bullets except opioids (placed under Contraindications) are listed.
9.3	Individual [caution_items] are formatted as <li></li>	🟢
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Example drug lists trimmed but kept; severity classes and time windows (24 hours, use days, separate use days, pulse below 50) preserved.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	ER uses no ranking notation.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	Section is populated, as the ER names interactions.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	Section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	No validated protocol, muscimol dose reference and single-versus-split dosing cover the ER Protocol’s core implementation points.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	ER names more than three protocol aspects.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Benefit timing (first evening), acute onset (30–120 minutes) and peak (2–3 hours, up to 24 hours) from ER Practical Considerations and Protocol.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Benefit-related timing placed first, followed by acute effect timing.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	ER provides three or more time-to-effect aspects.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	ER provides time-to-effect information.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Six Low and six Speculative items as bare names.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	benefits_high and benefits_medium set to display: none.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	The only parenthetical, “(sweating, salivation, slow heart rate)”, is part of the ER heading label itself, not a frequency, grade, sample note, mechanism or study.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	risks_high set to display: none.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All 7 ER table biomarkers plus baseline blood pressure listed.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Cadence matches the ER Monitoring paragraph.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All 6 ER qualitative markers listed verbatim.

Issues 29/09/2026 15:08

Pass rate 100.00%. No issues found.

Issues 29/09/2026 15:06

1. 1.1 — Invented blood pressure target: The Monitoring row “Blood pressure” (line 683) states the target “No target stated; baseline reference”, wording that does not appear in the ER; the ER lists blood pressure only as part of the baseline (ER line 413) and uses “No established target” as its own phrasing for a missing target.
2. 2.7 — Jargon risk label unexplained: The Risks Low tier (line 592) uses “Cholinergic symptoms” with no plain-language gloss, although the ER heading itself supplies one: “Cholinergic Symptoms (Sweating, Salivation, Slow Heart Rate)” (ER line 265).

Fixes 29/09/2026 15:06

1. 1.1 — Blood pressure target rewording: Changed the Blood pressure target from “No target stated; baseline reference” to “No established target; baseline before first use”, using the ER’s own empty-target phrasing and its baseline statement.
2. 2.7 — Cholinergic label glossed: Changed the Risks Low entry “Cholinergic symptoms” to the ER heading’s full wording, “Cholinergic symptoms (sweating, salivation, slow heart rate)”.

Issues 29/09/2026 15:01

1. 1.1 / 1.3 — Sleep apnea qualifier dropped: The Contraindications item at line 548 reads “untreated sleep apnea (15+ breathing pauses per hour)”, while the ER (line 335) specifies “untreated obstructive sleep apnea”; omitting “obstructive” widens the ER’s avoidance statement.

Fixes 29/09/2026 15:01

1. 1.1 / 1.3 — Sleep apnea qualifier restored: Changed the Contraindications item from “untreated sleep apnea (15+ breathing pauses per hour)” to “untreated obstructive sleep apnea (15+ breathing pauses per hour)” to match ER line 335.

Issues 29/09/2026 14:57

1. 4.5 — Sheet exceeds one A4 page: The Key Interactions gate (15 items, many with 3–4 example drugs, lines 559–573) and Contraindications (lines 542–551) wrap to two or more lines each in the half-width gates, pushing the sheet well past one A4 page; items are not trimmed to the one-page budget.
2. 8.5 — Opioid time window dropped: The Opioids contraindication (line 542) omits the ER qualifier “No safe interval is established; abstaining for 24 hours on either side of use”, which the parallel Alcohol item keeps.
3. 9.5 — Interaction qualifiers dropped: Heart-rate-lowering drugs (line 568) lose the ER threshold “bradycardia below 50 beats per minute”; Anticholinergic drugs (line 569) lose “avoiding them on use days”; Cannabis products (line 571) lose “separate use days”.

Fixes 29/09/2026 14:57

1. 4.5 — Gate items condensed: Trimmed example-drug lists and wording in the gates (e.g., benzodiazepines to “diazepam, zolpidem”, antiseizure to “valproate, topiramate”, sedating supplements to “kava, phenibut, valerian”, “15 or more” to “15+”, “24 hours on either side of use” to “24 hours either side”) to reduce rendered length.
2. 8.5 — Opioid time window restored: Opioids contraindication now reads “(oxycodone, morphine, methadone, tramadol; absolute contraindication; no safe interval established; 24 hours either side)”.
3. 9.5 — Interaction qualifiers restored: Added “pulse below 50 beats per minute” to heart-rate-lowering drugs, “avoid on use days” to anticholinergic drugs, and “separate use days” to cannabis products.

Issues 29/09/2026 14:54

1. 4.5 — Gates exceed one-page budget: Key Interactions (15 items, ~1,125 characters, lines 559–573) and Contraindications (10 items, ~740 characters, lines 542–551) are carried with near-full ER wording in half-width 9.5pt columns, pushing the sheet well beyond one A4 page instead of being condensed.

Fixes 29/09/2026 14:54

1. 4.5 — Condensed decision gate items: Shortened Key Interactions and Contraindications wording and trimmed example drug lists (e.g., “no safe interval is established; 24 hours on either side of use limits overlap” to “no safe interval established; 24 hours on either side of use”), keeping every item, threshold, time window and at least one named example.

Issues 29/09/2026 14:50

1. 1.2 — Alcohol safe-interval caveat dropped: Line 559 lists “Alcohol (avoid; 24 hours on either side of use)” without the ER’s cautious phrasing “No safe interval is established” (ER Key Interactions, Alcohol bullet), so the 24-hour window reads as an established safe interval.

Fixes 29/09/2026 14:50

1. 1.2 — Alcohol safe-interval caveat restored: Changed the Alcohol caution item from “Alcohol (avoid; 24 hours on either side of use)” to “Alcohol (avoid; no safe interval is established; 24 hours on either side of use limits overlap)”, matching the ER wording.

Issues 29/09/2026 14:48

1. 13.4 — Risk parenthetical not stripped: The Low risk tier (QRS line 592) keeps the parenthetical in “Cholinergic symptoms (sweating, salivation, slow heart rate)”; parenthetical content in risk items must be stripped.

Fixes 29/09/2026 14:48

1. 13.4 — Risk parenthetical stripped: Changed the Low risk item from “Cholinergic symptoms (sweating, salivation, slow heart rate)” to “Cholinergic symptoms”, removing the parenthetical.

Issues 29/09/2026 14:45

1. 14.2 — Sleep and mood log omitted: The ER biomarker table row “Sleep and mood log” (wearable sleep data and a 0–10 stress rating; target “No established target; track change from own baseline”) is absent from the Monitoring table and appears instead as qualitative_item_1 (QRS line 702).

Fixes 29/09/2026 14:45

1. 14.2 — Sleep and mood log restored: Added “Sleep and mood log” as Monitoring row marker_8 with the ER target “No established target; track change from own baseline” and why “Defines benefit”, and removed the duplicate qualitative item, renumbering the remaining six qualitative items.

Issues 29/09/2026 14:40

1. 1.2 — Cautious hedge dropped: At-A-Glance (line 433) ends “Its harms are more firmly established than its benefits”, omitting the ER Conclusion’s hedge “On current evidence,” (ER line 454).
2. 12.3 / 12.4 — Conflicted qualifier retained: benefits_low (line 528) and benefits_speculative (line 531) keep the parenthetical “(conflicted)” on “reduction of involuntary movements” and “anti-inflammatory effects”; tiered descriptors must carry no qualifiers or parenthetical content.
3. 14.2 — Blood pressure marker missing: The ER Monitoring section (line 413) names blood pressure as a measurable baseline marker, but the QRS Monitoring table (lines 611-678) omits it.

Fixes 29/09/2026 14:40

1. 1.2 — Cautious hedge restored: Changed the At-A-Glance closing sentence from “Its harms are more firmly established…” to “On current evidence, its harms are more firmly established…”, matching the ER Conclusion (70 words).
2. 12.3 / 12.4 — Conflicted qualifier removed: Stripped “(conflicted)” from “reduction of involuntary movements” in benefits_low and from “anti-inflammatory effects” in benefits_speculative.
3. 14.2 — Blood pressure marker added: Added a Monitoring row (marker_7) for blood pressure with target “No target stated; baseline reference” and why “Completes the baseline before first use”, per ER Monitoring line 413.

Issues 29/09/2026 14:37

1. 4.2 / 4.3 — Protocol labels not verbatim: The three action labels “Validated protocol”, “Muscimol dose reference” and “Timing” (QRS lines 444, 455, 466) paraphrase or invent labels instead of using the ER bold labels “No validated protocol”, “Muscimol-dosed approach” and “Single versus split dosing” (ER lines 357, 360, 366).

Fixes 29/09/2026 14:37

1. 4.2 / 4.3 — Protocol labels made verbatim: Changed the action labels from “Validated protocol”, “Muscimol dose reference” and “Timing” to the ER bold labels “No validated protocol”, “Muscimol-dosed approach” and “Single versus split dosing”; action_3_value changed from “Single evening dose” to “Single dose is standard” to match the relabeled ER bullet.